Imagine this: Amid the chaos of the COVID-19 pandemic, when families were already grappling with unprecedented health fears, prescriptions for crucial flu antivirals dropped dramatically for America's most vulnerable kids—those at high risk of severe illness. But here's where it gets controversial: despite more testing for influenza, doctors in emergency rooms prescribed these medications far less often. Could it be due to pandemic overload, misinformation, or something else entirely? Let's dive into the details of this eye-opening study and explore what it means for protecting our children from flu complications.
Topline:
The frequency of antiviral prescriptions handed out in emergency departments (EDs) for children deemed at high risk for severe flu complications fell by more than half during the later stages of the COVID pandemic compared to the pre-pandemic era, even as the proportion of kids getting tested for the flu rose significantly. For beginners wondering what this means, antiviral medications like oseltamivir (Tamiflu) are drugs designed to shorten the duration of the flu and reduce its severity, potentially preventing hospitalizations—especially vital for young children or those with underlying health issues who are more likely to face dangerous outcomes.
Methodology:
Researchers carried out a cross-sectional analysis using data from seven prominent US academic pediatric hospitals part of the CDC's New Vaccine Surveillance Network. Their goal? To track changes in antiviral prescriptions for at-risk children before COVID (from 2016 to 2020) versus the late pandemic years (2021 to 2023). Out of 3,378 kids who tested positive for influenza—with a median age of 3.9 years and about 53.2% being boys—2,514 were identified as high-risk, meaning they were either under 5 years old or had conditions affecting their respiratory system, heart, kidneys, liver, blood, metabolism, brain, or immune system. This included 583 cases from the late pandemic period and 1,931 from before. The team then analyzed shifts in prescription rates and the factors influencing them, ensuring a comprehensive look at how flu management evolved under pandemic pressures.
Takeaway:
And this is the part most people miss: antiviral prescriptions dipped from 32.2% in the pre-pandemic times to just 15.6% during the late pandemic—a relative decline of 53%. Yet, testing for influenza among these high-risk kids surged considerably in the later period. In 2021-2023, children who were tested and treated within two days of their symptoms appearing were far more likely to receive antivirals compared to those not tested (with an adjusted odds ratio, or aOR, of 17.20 and a 95% confidence interval of 4.08 to 72.37) or those seen later (aOR of 4.08, 95% CI 2.49 to 6.71). For clarity, an odds ratio here measures how much more probable an outcome is under certain conditions, adjusted for other variables. Overall, the chances of getting prescribed antivirals were markedly lower in the late pandemic than before (aOR 0.17, 95% CI 0.12 to 0.24), highlighting a potential gap in care.
In Practice:
These results underscore a troubling shortfall in how antiviral prescriptions are managed in EDs, the authors note. By understanding the drivers behind these trends, we can better shield at-risk pediatric patients from preventable flu-related suffering. For instance, consider a young child with asthma—timely antiviral treatment could mean the difference between a quick recovery at home and a scary hospital stay. 'The gap between testing and treatment points to a pressing need for doctors to follow guidelines on antiviral use,' the researchers emphasize, 'as starting treatment promptly has proven effective in lessening flu severity, shortening illness, and slashing complication risks, including admissions to the hospital.'
Source:
The study, spearheaded by Tess Stopczynski, MS, from Vanderbilt University Medical Center in Nashville, Tennessee, appeared online in JAMA Network Open on October 22, 2024 (accessible at https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2840397).
Limitations:
The researchers didn't delve into details like whether prescriptions were actually filled or if parents accepted them. Some participating sites limited antiviral use based on age (under 5) or symptom length (less than 10 days), and unaccounted-for factors might include widespread pandemic myths, overwhelming ED workloads, medication expenses, or parental worries about side effects—all of which could skew the findings.
Disclosures:
Funding came via the CDC's cooperative agreement IP16-004. Some authors disclosed receiving personal fees, grants, travel support, and advisory roles from pharmaceutical firms, institutions, and universities.
This piece was crafted with the help of various editorial tools, including AI, and underwent thorough review by human editors before going live.
What do you think sparked this drop in antiviral prescriptions during COVID? Was it overwhelmed healthcare workers, fear of drug side effects, or perhaps misinformation swirling online? And here's a controversial take: Could stricter pandemic protocols have inadvertently sidelined flu prevention for kids? Share your opinions below—do you agree or disagree, and what steps should we take to fix this?
